Displaying drugs 2676 - 2700 of 2779 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Resmetirom | 435.22 C17H12Cl2N6O4 |  | A thyroid hormone receptor-beta agonist used to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. | BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Pyrimidines / Pyrimidinones / Thyroid hormone receptor-beta (THR-beta) agonist / UGT1A4 Inhibitors / UGT1A9 Inhibitors |
| Light mineral oil | Not Annotated |  | An oil used to hydrate dry, itchy skin, hemorrhoids, and dry eyes. | Basic Ointments and Protectants |
| Opicapone | 413.17 C15H10Cl2N4O6 |  | A catechol-O-methyltransferase inhibitor used as an adjunct treatment for Parkinson's Disease in adults currently receiving levodopa and a dopa decarboxylase inhibitor. | COMT Inhibitors |
| Iodixanol | 1550.1819 C35H44I6N6O15 |  | A contrast agent used during coronary angiography, particularly in patients with renal dysfunction. | Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media |
| Simeprevir | 749.939 C38H47N5O7S2 |  | A direct-acting antiviral agent that inhibits HCV NS3/4A protease to treat chronic hepatitis C virus (HCV) infection in adults with HCV genotype 1 or 4. | Antivirals for treatment of HCV infections / Protease Inhibitors / Sulfonamides |
| Milnacipran | 246.354 C15H22N2O |  | A selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of fibromyalgia and a short-term treatment of major depressive disorder. | Agents producing tachycardia |
| Cefprozil | 389.426 C18H19N3O5S |  | A cephalosporin antibiotic used in the treatment of various bacterial infections, such as pharyngitis, tonsillitis, otitis media, and uncomplicated skin infections. | beta Lactam Antibiotics |
| Ecamsule | 562.69 C28H34O8S2 |  | A sunscreen agent found in sunscreens that absorbs UV rays. | Sunscreen Agents |
| Fluorodopa (18F) | 214.183 C9H10FNO4 |  | Fluorodopa F 18 is indicated for use with positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes... | Fluorine Radioisotopes |
| Osilodrostat | 227.242 C13H10FN3 |  | An oral inhibitor of cortisol synthesis used to treat Cushing's disease by normalizing hypercortisolism. | Anticorticosteroids |
| Guaifenesin | 198.2158 C10H14O4 |  | An expectorant commonly found in OTC products for the symptomatic relief from congested chests and coughs associated with cold, bronchitis, and/or other breathing illnesses. | Expectorants |
| Methoxyphenamine | 179.2588 C11H17NO |  | Not Annotated | Non-selective Beta-adrenergic Agonists |
| Methyl nicotinate | 137.136 C7H7NO2 |  | A methyl ester of niacin used to treat muscle and joint pain. | Anti-Inflammatory Agents / Erythema / Inflammation / Nicotinic Acids |
| Levobetaxolol | 307.434 C18H29NO3 |  | Used in the treatment of open-angle glaucoma and ocular hypertension [FDA Label]. | Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Bradycardia-Causing Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates |
| Fosphenytoin | 362.2739 C16H15N2O6P |  | An antiepileptic agent used for the management of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. | Anti-epileptic Agent / Hydantoins / Prodrugs / Sodium Channel Blockers |
| Gadopiclenol | 970.1 C35H54GdN7O15 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Contrast Media / Diagnostic Uses of Chemicals / Gadolinium-based Contrast Agent / Lanthanoid Series Elements / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Paramagnetic Contrast Agent / Paramagnetic Contrast Media |
| Desvenlafaxine | 263.3752 C16H25NO2 |  | An antidepressant agent and SNRI used for the treatment of major depressive disorders in adults. | Agents producing tachycardia |
| Venlafaxine | 277.4018 C17H27NO2 |  | A selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of major depression, generalized or social anxiety disorder, and panic disorder. | Agents producing tachycardia |
| Cobimetinib | 531.318 C21H21F3IN3O2 |  | An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. | Mitogen-activated protein kinase (MEK) inhibitors / Protein Kinase Inhibitors |
| Glimepiride | 490.62 C24H34N4O5S |  | A sulfonylurea drug used to treat type 2 diabetes mellitus. | Immunosuppressive Agents / Sulfonylureas |
| Linzagolix | 508.42 C22H15F3N2O7S |  | A selective gonadotropin-releasing hormone (GnRH) receptor antagonist used for the symptomatic treatment of uterine fibroids. | Anti-Gonadotropin-Releasing Hormones |
| Fedratinib | 524.678 C27H36N6O3S |  | Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016] | Janus Kinase Inhibitor / Protein Kinase Inhibitors |
| Ibrutinib | 440.507 C25H24N6O2 |  | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. | Bruton's tyrosine kinase (BTK) inhibitors / Protein Kinase Inhibitors |
| Lumacaftor | 452.414 C24H18F2N2O5 |  | A protein chaperone used in combination with ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the CFTR gene. | Amines / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Dioxoles / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inducers / P-glycoprotein inhibitors / Pyridines |
| Oteracil | 157.0843 C4H3N3O4 |  | A chemotherapy agent used in combination with tegafur, cisplatin and gimeracil to treat advanced gastric cancer. | Triazines |
Displaying drugs 2676 - 2700 of 2779 in total